How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
27
CVM Quote, Financials, Valuation and Earnings
Last price:
$5.75
Seasonality move
:
7.92%
Day range:
$5.43 - $6.01
52-week range:
$1.98 - $20.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.10x
Volume:
82.8K
Avg. volume:
83.6K
1-year change:
-51.61%
Market cap:
$17.6M
Revenue:
--
EPS (TTM):
-$5.45
Analysts' Opinion
-
Consensus RatingCEL-SCI Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $42.50, CEL-SCI Corp. has an estimated upside of 632.76% from its current price of $5.80.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $25.00 representing 100% downside risk from its current price of $5.80.
Fair Value
-
According to the consensus of 1 analyst, CEL-SCI Corp. has 632.76% upside to fair value with a price target of $42.50 per share.
CVM vs. S&P 500
-
Over the past 5 trading days, CEL-SCI Corp. has underperformed the S&P 500 by -0.85% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
CEL-SCI Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
CEL-SCI Corp. revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter CEL-SCI Corp. reported revenues of --.
Earnings Growth
-
CEL-SCI Corp. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter CEL-SCI Corp. reported earnings per share of -$0.76.
Enterprise value:
16M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-0.93x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$3.9M
Return On Assets:
-103.31%
Net Income Margin (TTM):
--
Return On Equity:
-230.36%
Return On Invested Capital:
-117.93%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$4M | -$4M | -$3.9M | -$991.6K | -$960.8K | |
| Operating Income | -$31.5M | -$26.4M | -$24.8M | -$6.1M | -$6M | |
| EBITDA | -$27.5M | -$22.4M | -$20.9M | -$5.1M | -$5.1M | |
| Diluted EPS | -$0.73 | -$3.28 | -$5.45 | -$2.87 | -$0.76 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $45.3M | $25.4M | $6.9M | $6.1M | $11.6M | |
| Total Assets | $75.9M | $50.5M | $30.5M | $27M | $28.2M | |
| Current Liabilities | $3.9M | $4.7M | $5.6M | $4.6M | $5.1M | |
| Total Liabilities | $19.3M | $18.4M | $17.3M | $14.1M | $12.2M | |
| Total Equity | $56.5M | $32.2M | $13.2M | $12.9M | $16M | |
| Total Debt | $15.9M | $15.1M | $13.4M | $11.4M | $9.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$20.5M | -$18.8M | -$17.1M | -$4.9M | -$4.7M | |
| Cash From Investing | -$372.3K | -$108.1K | -$38.1K | -$19.8K | -$5.2K | |
| Cash From Financing | $4.7M | $19.5M | $23.4M | $9.2M | $13.8M | |
| Free Cash Flow | -$20.9M | -$18.9M | -$17.2M | -$4.9M | -$4.7M | |
CVM
Sector
Market Cap
$17.6M
$24.3M
Price % of 52-Week High
28.42%
49.95%
Dividend Yield
0%
0%
Shareholder Yield
-88.17%
-1.67%
1-Year Price Total Return
-51.61%
-21.37%
Beta (5-Year)
0.538
0.484
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$6.02
200-day SMA
Sell
Level
$6.72
Bollinger Bands (100)
Sell
Level
5.56 - 9.08
Chaikin Money Flow
Sell
Level
-10.7K
20-day SMA
Buy
Level
$5.68
Relative Strength Index (RSI14)
Buy
Level
50.31
ADX Line
Sell
Level
13.78
Williams %R
Neutral
Level
-51.3514
50-day SMA
Sell
Level
$5.88
MACD (12, 26)
Buy
Level
0.82
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Sell
Level
-167.2K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-28.0811)
Sell
CA Score
(Annual)
Level (-4.418)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (6.8531)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.
Stock Forecast FAQ
In the current month, CVM has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CVM average analyst price target in the past 3 months is $42.50.
-
Where Will CEL-SCI Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that CEL-SCI Corp. share price will rise to $42.50 per share over the next 12 months.
-
What Do Analysts Say About CEL-SCI Corp.?
Analysts are divided on their view about CEL-SCI Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that CEL-SCI Corp. is a Sell and believe this share price will drop from its current level to $25.00.
-
What Is CEL-SCI Corp.'s Price Target?
The price target for CEL-SCI Corp. over the next 1-year time period is forecast to be $42.50 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CVM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for CEL-SCI Corp. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of CVM?
You can purchase shares of CEL-SCI Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase CEL-SCI Corp. shares.
-
What Is The CEL-SCI Corp. Share Price Today?
CEL-SCI Corp. was last trading at $5.75 per share. This represents the most recent stock quote for CEL-SCI Corp.. Yesterday, CEL-SCI Corp. closed at $5.80 per share.
-
How To Buy CEL-SCI Corp. Stock Online?
In order to purchase CEL-SCI Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get CVM Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CVM
Sector
P/E ratio
--
23.45x
PEG ratio
-0.02x
-0.01x
P/B ratio
1.10x
1.80x
Price / LTM sales
--
1.53x
Growth Metrics
CVM
Sector
Revenue growth
--
4.08%
Earnings growth
73.51%
9.94%
Revenue (5-year growth)
-100%
6.27%
Earnings forecast
--
-$0.19
Profitability
CVM
Sector
Profitability FY 2025
-$3.9M
$3M
Return on invested capital
-117.93%
-33.25%
Return on assets
-103.31%
-29.67%
Return on equity
-230.36%
-38.71%
Earnings Date
Last Earnings Date
Aug
14
Next Earnings Date
Feb
12
Estimated Next Earnings Date
Nov
13
Balance Sheet
CVM
Sector
Total cash
$11M
$25M
Short term investments
--
$25M
Total assets
$28.2M
$72.5M
Long term debt
$9.2M
$2.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Buy
60
JNUG alert for Jan 31
Direxion Daily Junior Gold Miners Idx Bull 2X Shs [JNUG] is down 26.98% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
